Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AGAP14P is annotated as a pseudogene in the human genome and is not believed to encode a functional protein. It is related to the ArfGAP subfamily (Arf GTPase-activating proteins), which generally function in membrane trafficking and actin cytoskeletal regulation, but AGAP14P itself does not encode a product with these functions[2][4]. AGAP protein family members, when functional, contain Arf GAP, GTPase-like, ankyrin repeat, and PH (pleckstrin homology) domains[1]. However, AGAP14P is not known to be functional and has no evidence of being involved as a therapeutic target, in disease processes, or as a molecular biomarker. There is no information available linking it to drug interactions, pharmacology, or clinical challenges. Summary of main issues: - AGAP14P is a pseudogene, meaning it is not expressed as a functional protein and does not perform canonical biological functions, nor does it have therapeutic relevance as a target[2][4]. - The presence of "pseudogene" in its name and annotation, with supporting evidence from major gene databases, indicates it should not be considered a real molecular target for drug discovery or clinical intervention. - No literature describes a disease implication, functional assays, biomarkers, or safety concerns related to AGAP14P. If you intended to obtain information about a functional protein from the AGAP family (e.g., AGAP1, AGAP2), those do have more established biological roles and can be explored separately[1]. AGAP14P specifically, however, is best classified as a non-functional genomic locus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ArfGAP with GTPase domain, ankyrin repeat and PH domain 14, pseudogene (AGAP14P).